Reportedly, Amgen Inc.’s (AMGN) Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial. Amgen is also testing whether the drug could be effective against lung cancer earlier in the disease, and informed that a small study of Lumakras combined with immunotherapy found high rates of liver toxicity, which requires further study.
Amgen said 33% of Lumakras trial patients experienced serious side effects such as diarrhea and elevated liver enzymes, compared with 40% of chemotherapy patients. The medication is designed to target a mutated form of a gene known as KRAS occurring in about 13% of non-small cell lung cancers which is the most common form of the disease.
The U.S. Food and Drug Administration also asked Amgen to study a lower dose of Lumakras, known chemically as sotorasib, the results of which are expected in the fourth quarter of this year. The agency is expected to make the approval on the KRAS-targeting drug, Mirati Therapeutics Inc’s adagrasib, a potential rival by this year mid-December.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
